Fortis Healthcare FY26 Performance and Future Plans

Fortis Healthcare's consolidated revenue for FY26 reached ₹9,128 crore, with a profit after tax of ₹1,064 crore. The company declared a dividend of ₹1 per share.

Reader Takeaway: Strong growth drivers and expansion plans, with potential regulatory headwinds.

What just happened

Fortis Healthcare reported robust financial figures for the financial year ending March 2026. Consolidated revenue stood at ₹9,128 crore, marking significant growth. The hospital business contributed ₹7,773 crore, while the diagnostics segment added ₹1,355 crore. Operating EBITDA rose 31.3% to ₹2,085 crore, and Profit After Tax (PAT) was ₹1,064 crore. For the fourth quarter of FY26, consolidated revenue was ₹2,365 crore, with PAT at ₹271 crore. Net debt stood at ₹2,334 crore, resulting in a net debt-to-EBITDA ratio of 1.09x.

Why this matters

These results indicate strong operational performance and profitability for Fortis Healthcare. The planned expansion of 1,800 beds over four years signals future growth potential. The declared dividend of ₹1 per share (10% of face value) shows a commitment to shareholder returns. Management's positive guidance for FY27, targeting 15%+ revenue growth in the hospital business and margin improvements, provides confidence in continued performance.

The backstory

In the past year, Fortis Healthcare added 800 beds to its network. The company's parent, IHH Healthcare, has indicated plans to increase its stake to 50% and potentially infuse ₹10,000 crore for growth.

What changes now

Fortis Healthcare is poised for further expansion with the planned addition of 1,800 beds. The company aims for 15%+ revenue growth and 150 basis points margin improvement in its hospital business for FY27. Diagnostic business EBITDA margins are projected between 23% and 24%.

Risks to watch

Concerns include a dip in occupancy in larger hospitals, attributed to slower international patient growth and medical oncology drug price capping in the Punjab/North region. Regulatory risks associated with oncology drug price capping may continue to impact revenue in specific segments like ECHS/CGHS.

Peer comparison

(No direct peer comparison data was provided in the filing.)

Context metrics (time-bound)

• Consolidated Revenue FY26: ₹9,128 crore
• Consolidated Operating EBITDA FY26: ₹2,085 crore
• Consolidated PAT FY26: ₹1,064 crore
• Net Debt as of March 31, 2026: ₹2,334 crore
• Net Debt to EBITDA Ratio: 1.09x
• Beds added in the past year: 800
• Beds planned over 4 years: 1,800

What to track next

Investors will be watching the execution of the bed expansion plan and the company's ability to navigate regulatory pricing pressures in oncology. Performance against the FY27 guidance for revenue growth and margin expansion will be key.